Working in close collaboration, the labs of Maria T. Diaz-Meco, Ph.D., and Jorge Moscat, Ph.D., found that PKCζ controls the activation of a pro-tumor gene called c-Myc. Normally, PKCζ’s alteration keeps c-Myc in check. But PKCζ levels are low in prostate and other cancers, leaving c-Myc free to enhance cell growth and metastasis. This study, appearing in the Proceedings of the National Academy of Sciences, suggests that restoring PKCζ could provide a new approach to treating prostate cancer. Read more here.
Study mentioned: Kim JY, et al. c-Myc phosphorylation by PKCζ represses prostate tumorigenesis. PNAS. Published online before print April 2, 2013.
No comments:
Post a Comment